查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969419

脑炎治疗市场：依治疗方法、药物类别、病患年龄层、给药途径、最终用户和销售管道划分－2026-2032年全球预测

Encephalitis Treatment Market by Treatment Type, Drug Class, Patient Age Group, Administration Route, End User, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑炎治疗市场价值将达到 164.8 亿美元，到 2026 年将成长至 175.4 亿美元，到 2032 年将达到 256.5 亿美元，复合年增长率为 6.51%。

主要市场统计数据
基准年 2025 164.8亿美元
预计年份：2026年 175.4亿美元
预测年份 2032 256.5亿美元
复合年增长率 (%) 6.51%

脑炎治疗趋势简述：重点在于诊断复杂性、不断发展的治疗方法以及创新与医疗保健服务之间的转化差距。

脑炎是指一组异质性脑部发炎性疾病，由于其神经功能迅速恶化、诊断复杂性以及病因多样（从感染疾病到免疫介导机制均有涉及），给临床治疗带来了紧迫的挑战。分子诊断、神经影像学和病原体特异性治疗方法的最新进展提高了治疗的速度和准确性，但仍存在一些系统性障碍，包括社区对脑炎的认知不足、抗病毒药物供应不均以及重症监护能力参差不齐。临床医生、医疗系统和研发人员必须权衡生物製药和抗病毒药物的快速创新与提供急性神经系统疾病护理所面临的持续性运作挑战。

诊断技术、标靶治疗和供应链策略的进步正在共同重新定义脑炎治疗的临床路径和商业模式。

诊断技术、标靶治疗和医疗服务模式的融合发展正在改变脑炎的治疗模式。快速分子检测和病原体特异性次世代定序缩短了诊断时间，使得病毒性脑炎患者能够更早接受标靶抗病毒药物治疗，并有助于将其与对免疫疗法有反应的自体免疫病因区分开来。同时，研发工作正从传统的核苷类似物扩展到更先进的免疫球蛋白製剂和辅助药物，以更有效地控制癫痫发作和颅内发炎。这些治疗创新与重症监护通讯协定和远距神经科支援的不断改进相辅相成，将专家的诊​​疗服务扩展到门诊和社区医院。

一项评估显示，2025 年实施的关税政策变化迫使製造商和医疗保健系统调整其供应链，包括脑炎治疗的采购、库存和合约策略。

美国2025年实施的关税政策调整增加了全球药品供应链的复杂性，对脑炎治疗相关的采购、筹资策略和製造商定价动态产生了下游影响。此次关税调整针对某些化学中间体和某些成品药，给常用抗病毒核苷类似物活性药物成分（API）以及静脉注射製剂所需成分的采购决策带来了压力。为因应这项变化，製造商加快了供应基地的多元化，将部分生产流程转移到免税地区，并增加了领先库存，以确保无菌注射剂的持续供应。

深度細項分析揭示了治疗方法、药物分类、给药途径、患者人口统计特征、医疗保健环境和销售管道如何相互作用，从而塑造临床和商业策略。

基于细分的分析方法阐明了影响产品开发和商业化策略的要素，例如治疗差异化、给药环境和以患者为中心的考量。治疗类型细分区分了预防和治疗方法。预防策略着重于疫苗研发，以预防脑炎的感染原因；而治疗方法包括抗病毒药物、免疫球蛋白疗法和综合支持性治疗。在抗病毒治疗中，阿昔洛韦、泛昔洛韦、膦甲酸钠、更昔洛韦和伐昔洛韦等已确立的核苷类似物仍是针对病原体干预的核心选择。药物类别细分进一步阐明了影响临床通讯协定和供应链需求的药理学类别。免疫球蛋白（主要是静脉注射免疫球蛋白製剂）在免疫介导的疾病中发挥核心作用，而核苷类似物是抗病毒治疗的基础。例如，焦磷酸盐类似物如膦甲酸钠，专门用于治疗抗药性或难治性病毒株；以及抗惊厥药和皮质类固醇等辅助疗法，用于缓解症状和控制发炎。

一项区域比较分析，展示了重点地区的基础设施、法规和製造能力如何决定脑炎治疗的临床引入和获取途径。

临床实务、法规结构和生产能力方面的区域差异对脑炎治疗方法在不同地区的研发、核准和分销产生了重大影响。在美洲，一体化的医疗保健系统和先进的检测网络能够快速引入分子诊断，并促进重症监护路径的建立；同时，支付方机制也推动了临床和经济价值证据的累积。欧洲、中东和非洲地区的特点是监管和基础设施环境的多样性，高度专业的医疗中心与重症监护资源有限的地区并存。这种异质性导致了区域性药物引进策略的差异，免疫球蛋白和抗病毒药物的供应也存在差异，并促使各地开展有针对性的能力建设倡议，以扩大诊断覆盖范围。亚太地区拥有强大的生产能力、广泛的临床试验活动和多样化的准入途径，其重点在于本地生产的学名药和创新生物製药，以及旨在应对脑炎感染因素的区域公共卫生计画。

决定脑炎治疗成功引入临床实践的关键策略行动和开发商、製造商和医疗保健系统之间的伙伴关係。

脑炎领域的商业性成功和临床影响取决于行业相关人员的策略行动，包括持续投资以产生临床证据、实现製造地多元化以及建立连接诊断和治疗的伙伴关係。领先的生物製药公司正日益重视平台技术，这些技术能够使其快速适应新出现的病毒威胁，并支持预防性疫苗计画以及治疗性单株抗体和免疫球蛋白产品。小规模的专业生物技术公司则专注于有限的适应症领域和快速的监管途径，利用适应性试验设计和真实世界数据来证明其在特定人群中的疗效。合约开发和生产组织（CDMO）在无菌注射剂和复杂生物製药的供应中发挥关键作用，推动上游工程合作以确保产能和品质保证。

为开发商、製造商和医疗保健系统提供可操作的策略步骤，以设计整合诊断、确保供应和加速治疗效果的进入途径。

产业和医疗系统领导者应优先采取一系列综合行动，以充分利用治疗技术的进步，并加强那些阻碍及时治疗的弱点。首先，将临床开发与可操作的诊断演算法相结合，确保新疗法在真实世界的患者识别流程中进行评估，并伴随诊断与候选疗法同步检验。其次，实现关键药物活性成分和无菌生产能力的供应链多元化，以减少对单一来源的依赖，并在政策和贸易中断的情况下保持供应的连续性。第三，制定针对不同给药途径和医疗环境的药物策略。静脉注射产品需要投资于输液能力和住院合同，而口服疗法则受益于门诊病人配送模式和药物支持。

高度透明的混合调查方法结合了专家访谈、文献整合和交叉检验，从而得出关于脑炎治疗的可重复、实用的见解。

本研究采用混合方法，结合一手和二手证据收集，并运用严格的三角验证法，以确保分析的有效性和实际应用价值。一手资料包括对神经科、感染疾病专家、医院药剂师和供应链管理人员的结构化访谈，并辅以专家咨询小组对临床实践趋势和药物应用决策的评估。二级资讯来源包括同侪审查的临床文献、监管指导文件、临床试验註册资讯和公共卫生监测报告，提供疾病病因模式和药物使用方面的背景资讯。数据整合强调临床、监管和商业领域之间的时间一致性，以反映最新的临床实践模式和政策趋势。

总之，这项综合分析强调，协作证据的产生、稳健的供应策略以及诊断和治疗的整合是脑炎治疗临床和商业性成功的关键。

脑炎治疗正处于转折点，诊断速度加快、治疗方法多样化以及供应链监管加强，为相关人员带来了机会和责任。临床实务正转向利用分子诊断技术进行病原体特异性早期疗育，治疗方案也不断扩展，包括更有效的抗病毒药物、免疫球蛋白以及针对神经系统后遗症的支持性治疗。同时，贸易中断和不断变化的报销预期等政策和商业性压力，要求各方积极规划，以确保产品的供应和可负担性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的脑炎治疗市场

  • 预防
  • 治疗药物
    • 抗病毒治疗
      • 阿昔洛韦
      • 泛昔洛韦
      • 福斯卡内特
      • 更昔洛韦
      • 伐昔洛韦
    • 免疫球蛋白
    • 支持性护理

第九章：脑炎治疗市场：依药物类别划分

  • 免疫球蛋白
  • 核苷类似物
    • 阿昔洛韦
    • 泛昔洛韦
    • 更昔洛韦
    • 伐昔洛韦
  • 焦磷酸盐类似物
  • 支持治疗药物
    • 抗惊厥药物
    • 皮质类固醇

第十章：依患者年龄层分類的脑炎治疗市场

  • 成人版
  • 新生
  • 儿童

第十一章：依给药途径分類的脑炎治疗市场

  • 静脉注射
  • 口服

第十二章：脑炎治疗市场：依最终用户划分

  • 门诊部
  • 医院
  • 研究机构
  • 专科诊所

第十三章：脑炎治疗市场：依销售管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章：脑炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：脑炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 脑炎治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国脑炎治疗市场

第十八章：中国脑炎治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Biotest AG
  • CSL Behring LLC
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Grifols, SA
  • Johnson & Johnson
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-535C629188F4

The Encephalitis Treatment Market was valued at USD 16.48 billion in 2025 and is projected to grow to USD 17.54 billion in 2026, with a CAGR of 6.51%, reaching USD 25.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.48 billion
Estimated Year [2026] USD 17.54 billion
Forecast Year [2032] USD 25.65 billion
CAGR (%) 6.51%

A concise orienting summary of encephalitis therapeutic dynamics highlighting diagnostic complexity, evolving treatments, and the translational gap between innovation and care delivery

Encephalitis encompasses a heterogeneous set of inflammatory conditions of the brain that present an urgent clinical challenge due to rapid neurological deterioration, diagnostic complexity, and diverse etiologies that span infectious agents and immune-mediated mechanisms. Recent advancements in molecular diagnostics, neuroimaging, and pathogen-specific therapeutics have improved the timeliness and precision of care, yet systemic barriers remain, including delayed recognition in community settings, gaps in antiviral availability, and variability in supportive critical care capacity. Clinicians, health systems, and developers must reconcile the accelerating pace of biologic and antiviral innovation with persistent operational challenges in delivering acute neurologic care.

This report distills clinical trends, therapeutic modalities, regulatory shifts, and commercial dynamics relevant to stakeholders across development, manufacturing, clinical practice, and payers. It synthesizes evidence on prophylactic and therapeutic approaches, evolving drug classes, administration routes, age-group considerations, end-user settings, and sales channels. By integrating clinical practice patterns with supply chain and policy developments, the report provides a pragmatic framework to prioritize research investments, optimize distribution strategies, and enhance patient access pathways. Transitioning from insight to action requires a clear understanding of where therapeutic efficacy, real-world implementation, and commercial viability intersect, and this analysis is structured to support that translational pathway.

How advances in diagnostics, targeted therapies, and supply chain strategies are collectively redefining clinical pathways and commercial models for encephalitis care

The landscape for encephalitis treatment is undergoing a transformative shift driven by convergent advances in diagnostics, targeted therapeutics, and healthcare delivery models. Rapid molecular assays and pathogen-specific next-generation sequencing have compressed diagnostic timelines, enabling earlier initiation of targeted antivirals for viral encephalitis and facilitating differentiation from autoimmune etiologies that respond to immunotherapy. Concurrently, development activity has expanded beyond traditional nucleoside analogues to include refined immunoglobulin formulations and adjunctive supportive agents that address seizures and intracranial inflammation more effectively. These therapeutic innovations are complemented by iterative improvements in critical care protocols and tele-neurology support, which extend specialist expertise into ambulatory and community hospital settings.

Commercially, manufacturers are reconfiguring supply chains to reduce single-source dependencies for active pharmaceutical ingredients and sterile injectables, and strategic partnerships between biotechs and contract manufacturers have accelerated launch-readiness timelines. Regulatory pathways have also adapted, with agencies showing increased flexibility for trials in rare and severe acute conditions when meaningful clinical endpoints and robust real-world evidence strategies are presented. Together, these shifts are reshaping clinical practice patterns and creating new opportunities for integrated product-service offerings that combine therapeutics, diagnostics, and implementation support to improve time-to-treatment and patient outcomes.

Assessment of how tariff-driven supply chain adjustments in 2025 compelled manufacturers and health systems to reconfigure sourcing, inventory, and contracting strategies for encephalitis therapeutics

United States tariff policy changes enacted in 2025 introduced added complexity to global pharmaceutical supply chains, with downstream effects on procurement, sourcing strategies, and manufacturer pricing dynamics relevant to encephalitis treatments. Tariff adjustments targeted specific chemical intermediates and certain finished pharmaceutical goods, which pressured sourcing decisions for active pharmaceutical ingredients commonly used in antiviral nucleoside analogues and for components required for intravenous formulation delivery. In response, manufacturers accelerated diversification of supplier bases, relocated select production stages to tariff-favored jurisdictions, and increased forward inventory buffers to maintain continuity of sterile injectable supply.

These operational responses also influenced commercial contracting and payer negotiations. Health systems and hospital pharmacies reassessed formulary choices and procurement frameworks to maintain affordability and availability of first-line antivirals and supportive agents. Regulatory stakeholders emphasized the importance of transparent supply chain mapping to preempt shortages, and multi-stakeholder task forces emerged to coordinate contingency plans for essential neurocritical care therapeutics. Meanwhile, clinical developers factored tariff-driven cost volatility into pricing strategy deliberations and into clinical supply planning, with an emphasis on securing multi-source manufacturing to protect trial continuity. Collectively, the tariff-driven environment in 2025 catalyzed resilience-focused investments in sourcing, inventory management, and collaborative procurement across the encephalitis therapeutic ecosystem.

Deep segmentation insights revealing how treatment modality, drug class, administration route, patient demographics, care settings, and sales channels jointly shape clinical and commercial strategies

A segmentation-informed lens clarifies therapeutic differentiation, delivery settings, and patient-centric considerations that shape product development and commercialization strategies. Treatment-type segmentation delineates prophylactic and therapeutic pathways, with prophylactic strategies centered on vaccine development to prevent infectious causes of encephalitis, while therapeutic approaches encompass antiviral agents, immunoglobulin therapies, and comprehensive supportive care regimens; within antiviral therapies, established nucleoside analogues such as acyclovir, famciclovir, foscarnet, ganciclovir, and valacyclovir continue to serve as core options for pathogen-directed intervention. Drug-class segmentation further explicates pharmacologic categories that influence clinical protocols and supply chain needs, with immunoglobulins-predominantly intravenous immunoglobulin formulations-playing a central role in immune-mediated presentations, nucleoside analogues forming the backbone of antiviral treatment, pyrophosphate analogues represented by agents such as foscarnet reserved for resistant or refractory viral strains, and supportive agents including anticonvulsants and corticosteroids addressing symptom control and inflammation management.

End-user segmentation highlights that hospitals and specialty clinics remain critical nodes for acute management and complex diagnostic workflows, while ambulatory care centers and research institutes drive early intervention pathways and evidence generation respectively. Administration-route segmentation underscores the operational differences between intravenous and oral regimens, with intravenous delivery necessitating infusion capacity, cold chain considerations, and sterile manufacturing controls, whereas oral agents enable outpatient therapy and broader distribution through retail and online pharmacy channels. Patient age-group segmentation-distinguishing adult, neonatal, and pediatric populations-introduces clinically meaningful differences in dosing, safety profiles, and regulatory requirements, prompting differentiated clinical trial designs and age-specific labeling strategies. Finally, sales-channel segmentation captures the distribution nuances across hospital pharmacy networks, online pharmacy platforms, and retail pharmacy outlets, each presenting distinct contracting, reimbursement, and adherence dynamics that must be addressed in launch planning and lifecycle management.

Comparative regional analysis showing how infrastructure, regulation, and manufacturing capacity across major geographies determine clinical adoption and access pathways for encephalitis therapies

Regional variations in clinical practice, regulatory frameworks, and manufacturing capacity materially influence how therapies for encephalitis are developed, approved, and delivered across geographies. In the Americas, integrated health systems and advanced laboratory networks enable rapid adoption of molecular diagnostics and facilitate centralized acute care pathways, while payer structures incentivize evidence generation that demonstrates clinical and economic value. Europe, Middle East & Africa represents a diverse regulatory and infrastructure landscape where high-capacity centers of excellence coexist with regions facing constrained critical care resources; this heterogeneity drives localized adoption strategies, differential utilization of immunoglobulins and antivirals, and targeted capacity-building initiatives to expand diagnostic reach. Asia-Pacific combines significant manufacturing capability, a broad spectrum of clinical trial activity, and variable access pathways, leading to a dual focus on locally produced generics and innovative biologics, alongside regionally scaled public health programs to address infectious drivers of encephalitis.

Across these regions, cross-border collaboration on surveillance, pathogen sequencing, and clinical trial networks is increasingly important for generating robust evidence and for harmonizing treatment guidelines. Regional procurement mechanisms and regulatory convergence efforts offer pathways to streamline approvals and distribution for critical therapeutics, while differences in hospital infrastructure and outpatient care models necessitate tailored launch and access strategies to ensure equitable delivery of advanced therapies.

Key strategic behaviors and partnerships among developers, manufacturers, and health systems that determine successful translation of encephalitis therapeutics into clinical practice

Commercial success and clinical impact in the encephalitis space hinge on a constellation of strategic behaviors by industry participants, including sustained investment in clinical evidence generation, diversification of manufacturing footprints, and partnerships that bridge diagnostics and therapeutics. Leading biopharmaceutical organizations increasingly prioritize platform technologies that enable rapid adaptation to emergent viral threats and that support both prophylactic vaccine programs and therapeutic monoclonal or immunoglobulin products. Smaller specialty biotechs focus on niche indications and accelerated regulatory pathways, leveraging adaptive trial designs and real-world evidence to demonstrate efficacy in limited populations. Contract development and manufacturing organizations play a pivotal role in supplying sterile injectables and complex biologics, prompting upstream collaborations to ensure capacity and quality assurance.

Strategic commercial alliances between diagnostics companies and therapeutic developers are also gaining prominence, as integrated offerings that combine rapid pathogen detection with targeted drug delivery can materially shorten time-to-treatment and improve outcomes. Payers and hospital systems, for their part, are signaling a preference for value-based contracts and outcomes-aligned agreements that mitigate budgetary risk while supporting access to high-cost but clinically necessary interventions. Across the ecosystem, companies that proactively address supply continuity, evidence differentiation, and clinician education are best positioned to translate clinical promise into sustainable therapeutic adoption.

Actionable strategic steps for developers, manufacturers, and health systems to integrate diagnostics, secure supply, and design access pathways that accelerate therapeutic impact

Leaders across industry and health systems should prioritize an integrated set of actions to capitalize on therapeutic advances and shore up vulnerabilities that impede timely treatment. First, align clinical development with pragmatic diagnostic algorithms to ensure that novel therapeutics are evaluated in the context of real-world patient identification workflows and that companion diagnostics are validated alongside therapeutic candidates. Second, diversify supply chains for critical active pharmaceutical ingredients and sterile production capabilities to reduce single-source exposure and to maintain continuity in the face of policy or trade disruptions. Third, tailor access strategies to administration route and care setting; intravenous products require investment in infusion capacity and inpatient contracting, whereas oral therapies benefit from outpatient distribution models and adherence support.

Additionally, develop age-specific clinical programs that address neonatal, pediatric, and adult safety and efficacy considerations early in development, and proactively engage regulatory authorities with robust pediatric investigation plans where applicable. Strengthen payer-engagement plans by generating outcomes-based evidence and by proposing contracting mechanisms that align therapeutic reimbursement with measurable clinical benefit. Finally, invest in clinician and system-level education to accelerate guideline adoption, and support point-of-care diagnostic deployment in community settings to improve early recognition and treatment initiation. These coordinated measures will materially advance both clinical outcomes and the commercial viability of new encephalitis therapies.

A transparent mixed-methods research framework combining expert interviews, literature synthesis, and cross-validation to produce reproducible and actionable insights into encephalitis therapeutics

This research employs a mixed-methods approach combining primary and secondary evidence collection with rigorous triangulation to ensure analytic validity and pragmatic relevance. Primary inputs include structured interviews with neurologists, infectious disease specialists, hospital pharmacists, and supply chain executives, supplemented by expert advisory panels that evaluate clinical practice trends and formulary decision-making. Secondary sources encompass peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and public health surveillance reports that provide context on etiology patterns and therapeutic use. Data synthesis emphasizes temporal alignment across clinical, regulatory, and commercial domains to reflect the most current practice patterns and policy developments.

Analytic methods integrate qualitative thematic analysis with cross-sectional mapping of therapy-to-setting fit, route-of-administration implications, and supply chain dependencies. Quality control procedures include cross-validation of interview insights against documented clinical guidelines and a structured review of regulatory precedents. Ethical considerations were applied throughout, ensuring that all primary research complied with confidentiality requirements and that expert contributions were de-identified in aggregated findings. The research design prioritizes reproducibility and transparency, with methodological appendices detailing interview protocols, search strategies, and criteria for source inclusion and exclusion.

Concluding synthesis emphasizing how coordinated evidence generation, resilient supply strategies, and diagnostic-therapeutic integration will determine clinical and commercial success in encephalitis care

Encephalitis treatment is at an inflection point where diagnostic acceleration, therapeutic diversification, and heightened supply chain scrutiny converge to create both opportunities and responsibilities for stakeholders. Clinical practice is shifting toward earlier pathogen-specific intervention enabled by molecular diagnostics, while therapeutic pipelines expand to include refined antivirals, immunoglobulin formulations, and supportive agents that address neurologic sequelae. Simultaneously, policy and commercial pressures-exemplified by trade-related disruptions and evolving reimbursement expectations-require proactive planning to ensure product availability and affordability.

Ultimately, progress in this field will depend on integrated strategies that synchronize clinical evidence generation with operational readiness: aligning diagnostics and therapeutics, securing resilient manufacturing and distribution networks, and engaging payers with meaningful outcomes data. When these components are effectively coordinated, patients stand to benefit from timelier, more targeted care; health systems can reduce variability in outcomes; and developers can achieve more sustainable adoption pathways for novel interventions. Continued collaboration across clinical, regulatory, and commercial stakeholders will be essential to translate scientific advances into consistent improvements in encephalitis care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Encephalitis Treatment Market, by Treatment Type

  • 8.1. Prophylactic
  • 8.2. Therapeutic
    • 8.2.1. Antiviral
      • 8.2.1.1. Acyclovir
      • 8.2.1.2. Famciclovir
      • 8.2.1.3. Foscarnet
      • 8.2.1.4. Ganciclovir
      • 8.2.1.5. Valacyclovir
    • 8.2.2. Immunoglobulin
    • 8.2.3. Supportive Care

9. Encephalitis Treatment Market, by Drug Class

  • 9.1. Immunoglobulins
  • 9.2. Nucleoside Analogues
    • 9.2.1. Acyclovir
    • 9.2.2. Famciclovir
    • 9.2.3. Ganciclovir
    • 9.2.4. Valacyclovir
  • 9.3. Pyrophosphate Analogues
  • 9.4. Supportive Agents
    • 9.4.1. Anticonvulsant
    • 9.4.2. Corticosteroid

10. Encephalitis Treatment Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Neonatal
  • 10.3. Pediatric

11. Encephalitis Treatment Market, by Administration Route

  • 11.1. Intravenous
  • 11.2. Oral

12. Encephalitis Treatment Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes
  • 12.4. Specialty Clinics

13. Encephalitis Treatment Market, by Sales Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Encephalitis Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Encephalitis Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Encephalitis Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Encephalitis Treatment Market

18. China Encephalitis Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ADMA Biologics, Inc.
  • 19.6. Baxter International Inc.
  • 19.7. Biotest AG
  • 19.8. CSL Behring LLC
  • 19.9. Emergent BioSolutions Inc.
  • 19.10. GlaxoSmithKline plc
  • 19.11. Grifols, S.A.
  • 19.12. Johnson & Johnson
  • 19.13. Kedrion S.p.A.
  • 19.14. LFB S.A.
  • 19.15. Octapharma AG
  • 19.16. Pfizer Inc.
  • 19.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENCEPHALITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PYROPHOSPHATE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PYROPHOSPHATE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PYROPHOSPHATE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTICONVULSANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTICONVULSANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY NUCLEOSIDE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)